A report at the 20th World Lung Cancer Congress (WCLC) also pointed out that the glucose transporter (GLUT3/GLUT1 ratio) could predict the immunotherapy response of lung cancer (Na et al., 2019). This evidence concerns the gene SLC2A3 and lung carcinoma.